Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Maintenance in LA-HNSCC
NCT06240689Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06240689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240689.